<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880708</url>
  </required_header>
  <id_info>
    <org_study_id>2017-950-2</org_study_id>
    <nct_id>NCT03880708</nct_id>
  </id_info>
  <brief_title>China Inherited Ventricular Arrhythmias Registry</brief_title>
  <official_title>China Inherited Ventricular Arrhythmias Registry, a Multicenter, Observational and Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, prospective, multi-center registry, aiming at building a risk
      stratification for malignant inherited ventricular arrhythmias, including Brugada
      syndrome(Brs)、Long QT syndrome(LQTS)、Short QT syndrome(SQTS)、Early repolarization
      syndrome(ERS) and Catecholaminergic polymorphic ventricular tachycardia(CPVT). 500
      participants will be recruited from 10 centers in China, with clinical data to be abstracted
      from medical records, and blood samples to be collected for finding related genes and
      promising risk indicators. The follow-up should be made every 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In China, the prevalence and risk factors of malignant ventricular arrhythmias remain
      unclear. In addition, mainstream treatment relies on implantable devices and medication.
      China Malignant Ventricular Arrhythmias Study is a nation-wide complex consisting of several
      interrelated studies, with the aim of building a risk stratification as well as an efficient
      and economic strategy for early prevention and treatment.

      Inherited Ventricular Arrhythmias Registry, as a part of China Malignant Ventricular
      Arrhythmias Study, is an observational, prospective, multi-center registry, aiming at
      exploring the correlation between genotype and phenotype for inherited structural ventricular
      arrhythmias, thus helping molecular diagnosis and risk stratification of these conditions.
      500 patients with definitive diagnosis will be recruited consecutively from 10 major
      arrhythmia centers distributed in 6 areas in China. At study entry, participants will be
      interviewed and asked to sign the informed consent. Demographic characteristics, medical
      history, clinical features, laboratory tests, imaging pictures, medications, procedures, and
      in-hospital outcomes of patients will be abstracted from medical records by well-trained
      staffs. At the same time, blood samples will be collected to detect biological markers, like
      genes, inflammatory factors ,etc. Once enrolled, the participants will receive follow up
      every 6 mouths about condition of arrhythmia, medication, clinical events, etc.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Anticipated">October 24, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 24, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sustained tachycardia/ ventricular fibrillation or sudden cardiac death</measure>
    <time_frame>5 years</time_frame>
    <description>event of sustained ventricular tachycardia/ ventricular fibrillation or sudden cardiac death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>episodes of arrhythmia</measure>
    <time_frame>5 years</time_frame>
    <description>type of arrhythmia, the amount of episodes, duration, unstable hemodynamics, treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause death</measure>
    <time_frame>5 years</time_frame>
    <description>exclude accidents, like trauma, drowning</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Ventricular Arrythmia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample will be collected from enrolled participants to detect biomarkers, like genes,
      inflammatory factors ,etc.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In 10 major arrhythmia centers distributed in 6 areas in China, 500 patients satisfying the
        inclusion criteria will be enrolled consecutively
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed as Brugada syndrome(Brs)、Long QT syndrome(LQTS)、Short QT
             syndrome(SQTS)、Early repolarization syndrome(ERS) or Catecholaminergic polymorphic
             ventricular tachycardia(CPVT).

        Exclusion Criteria:

          -  patients were enrolled by other clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan YAO, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>China National Center for Cardiovascular Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan YAO, MD,PhD</last_name>
    <phone>+86-13901121319</phone>
    <email>ianyao@263.net.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shangyu LIU, MD</last_name>
    <phone>+86-18800161355</phone>
    <email>liushangyu_yu_fw@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China National Center for Cardiovascular Diseases</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan YAO, MD, PhD</last_name>
      <phone>+86-13901121319</phone>
      <email>ianyao@263.net.cn</email>
    </contact>
    <contact_backup>
      <last_name>Shangyu LIU, MD</last_name>
      <phone>+86-18800161355</phone>
      <email>liushangyu_fw@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 17, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 22, 2019</last_update_submitted>
  <last_update_submitted_qc>March 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brugada syndrome</keyword>
  <keyword>long QT syndrome</keyword>
  <keyword>short QT syndrome</keyword>
  <keyword>early repolarization syndrome</keyword>
  <keyword>catecholaminergic polymorphic ventricular tachycardia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

